1. Home
  2. MRAM vs BMEA Comparison

MRAM vs BMEA Comparison

Compare MRAM & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Everspin Technologies Inc.

MRAM

Everspin Technologies Inc.

HOLD

Current Price

$8.78

Market Cap

202.3M

Sector

Technology

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.12

Market Cap

90.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRAM
BMEA
Founded
2008
2017
Country
United States
United States
Employees
85
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
202.3M
90.5M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
MRAM
BMEA
Price
$8.78
$1.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
7
Target Price
$14.00
$8.71
AVG Volume (30 Days)
419.8K
914.6K
Earning Date
03-04-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$49,417,000.00
N/A
Revenue This Year
$10.87
N/A
Revenue Next Year
$8.33
N/A
P/E Ratio
N/A
N/A
Revenue Growth
37.51
N/A
52 Week Low
$4.34
$0.87
52 Week High
$17.24
$3.08

Technical Indicators

Market Signals
Indicator
MRAM
BMEA
Relative Strength Index (RSI) 36.83 35.62
Support Level $8.42 $1.03
Resistance Level $9.74 $1.45
Average True Range (ATR) 0.56 0.10
MACD -0.01 -0.04
Stochastic Oscillator 6.20 5.88

Price Performance

Historical Comparison
MRAM
BMEA

About MRAM Everspin Technologies Inc.

Everspin Technologies Inc is a manufacturer of Magnetoresistive Random Access Memory (MRAM) technology. The company manufactures MRAM products using both captive and third-party manufacturing capabilities. It purchases industry-standard complementary metal-oxide semiconductor (CMOS) wafers from semiconductor foundries and perform back end of line (BEOL) processing that includes magnetic-bit technology at leased 200mm fabrication facility in Chandler, Arizona. It also manufactures full-flow 300mm CMOS wafers with STT-MRAM magnetic-bit technology integrated in BEOL. The company's customers are in key markets, such as industrial, medical, automotive/transportation, aerospace, and data center.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: